Drugs / Panzyga
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04153422 | Dec 2023 → Aug 2027 expected | autoimmune neuropathy, neuropathy, small fiber, polyneuropathy | Endeavor Health | Recruiting | No outcome recorded |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT04929236 | Oct 2023 → Dec 2028 expected | polyneuropathy, inflammatory demyelinating, chronic | Octapharma | Recruiting | No outcome recorded |
| Phase 3 | NCT04508530 | Jun 2021 → Aug 2024 | pediatric acute-onset neuropsychiatric syndrome | Octapharma | Completed | Missed primary |
| Phase 3 | NCT04502030 | Oct 2020 → Sep 2025 | B cell deficiency, B-cell chronic lymphocytic leukemia | Octapharma | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03866798 | Jan 2020 → Sep 2023 | autoimmune thrombocytopenia | Octapharma | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07220915 Comparator | Jun 2026 → Dec 2029 expected | autoimmune disease, dysgammaglobulinemia, infectious disease, rheumatic disorder | Octapharma | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Panzyga | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03866798 ↗ |
| Modality | Protein / enzyme biologic | “Immune Globulin” NCT03866798 ↗ |
| Route | Intravenous | “intravenous” NCT03866798 ↗ |